NCT06188325View on ClinicalTrials.gov

A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

March 26, 2018

Study Completion Date

March 26, 2018

Conditions
Gaucher's Disease
Interventions
DRUG

Eliglustat

Pharmaceutical form:Capsule-Route of administration:Oral

Trial Locations (1)

75247

M.D.Covance Clinical Research Unit 1341 W, Dallas

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT06188325 - A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers | Biotech Hunter | Biotech Hunter